Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | BAP1 | Q92560 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258342 | 0.87 | HPRT1 (0.48) | ALDH1A1HPRT1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL7571975 | 0.81 | HDAC3 (0.48) | THRBALDH1A1NAMPTHPRT1MAPT | |
| SCHEMBL7567089 | 0.77 | HPRT1 (0.54) | HPRT1USP2HSD17B10CASP7 | |
| SCHEMBL7570471 | 0.77 | HPRT1 (0.48) | GAAALDH1A1HPRT1MAPTMEN1 | |
| SCHEMBL7570108 | 0.74 | HPRT1 (0.42) | ALDH1A1HPRT1POLB | |
| SCHEMBL7982326 | 0.73 | HPRT1 (0.51) | GAAALDH1A1HPRT1MAPTKDM4E | |
| SCHEMBL7570074 | 0.72 | HPRT1 (0.53) | GAAALDH1A1HPRT1KMT2AHPGD | |
| SCHEMBL7570874 | 0.71 | HPRT1 (0.45) | THRBALDH1A1HPRT1MAPTPOLB | |
| SCHEMBL7570941 | 0.71 | HPRT1 (0.49) | HPRT1 | |
| SCHEMBL7576799 | 0.71 | HPRT1 (0.51) | HPRT1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | claimed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | GAP43, BDNF, APP | THRB 3032/4885GAA 416/4885ALDH1A1 2867/4885 |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | THRB 3527/4885GAA 1184/4885ALDH1A1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.